Charles Barkley’s Weight Loss and Ill-Fitting Suits Spark Online Memes Charles Barkley, the 63-year-old former NBA star, has undergone a dramatic weight loss of 85 pounds over the past few years, transforming his physique significantly. However, his recent appearances have drawn attention for his ill-fitting suits, which have become a source of humor and criticism online. Despite his physical transformation, Barkley’s wardrobe choices have raised eyebrows, with many noting that his suits appear oversized and unflattering. The 11-time NBA All-Star, who was listed at 250 pounds throughout his professional career, gained over 100 pounds by 2020, reaching a weight of more than 350 pounds. His weight loss journey began in 2023 with the use of GLP-1 medications, including Mounjaro and Zepbound, and he has since become the face of Ro, a pharmaceutical company. These drugs, originally designed to manage diabetes, work by mimicking a hormone released after eating, which helps regulate blood sugar levels, slow stomach emptying, and promote a feeling of fullness. While primarily intended for diabetes treatment, many users, including Barkley, have adopted them for weight management, alongside improved diet and increased physical activity. Barkley’s recent return as a March Madness analyst highlighted the issue. During a studio appearance, his suit was described as baggy, with sleeves that hung loosely and a head-to-body proportion that appeared disproportionate. Social media users quickly took notice, comparing his look to a child wearing his father’s clothes. Memes and tweets mocked the situation, with one user writing, “People thought he looked like a kid wearing their dad’s suit.” Another joked, “Why does Charles Barkley look like a child wearing their father’s suit? Someone get this man a tailor 😭 #MarchMadness.#charles_barkley #zepbound #march_madness #mounjaro #ro_pharmaceuticals
Novo Nordisk ends legal proceedings against Hims & Hers Hims & Hers shares surged after Novo Nordisk announced it would drop its patent infringement lawsuit against the telehealth provider. The decision followed an agreement between the two companies, which includes Hims offering Novo’s branded weight-loss drugs at the same price as other telehealth platforms and ceasing to advertise compounded GLP-1 drugs. Novo Nordisk CEO Mike Doustdar stated the legal case would be dropped, though the company reserved the right to revisit it if necessary. The agreement also involves Hims selling injectable and oral semaglutide, marketed as Ozempic and Wegovy, through its platform at prices comparable to other telehealth services. Hims will no longer promote compounded versions of GLP-1 drugs, which are unapproved by the FDA. The move comes after Novo accused Hims of selling counterfeit versions of Wegovy at a significantly lower price, which sparked backlash from both the company and the U.S. Food and Drug Administration. Hims’ shares rose over 40% in early trading, while Novo’s stock gained 2.1%. The FDA’s commissioner, Marty Makary, praised the agreement, emphasizing that Hims will provide affordable, FDA-approved medications and limit compounded drugs to rare cases. Makary noted that Hims’ shift away from unapproved compounded products aligns with regulatory efforts to curb illegal compounding practices. The dispute began in February when Novo sued Hims for selling a copycat version of Wegovy at $49, far below the branded price. Hims quickly halted the sale after pressure from Novo and the FDA, which warned of potential legal violations. The FDA has since pledged to take action against compounding pharmacies and referred Hims to the Department of Justice for further review.#hims_hers #novonordisk #marty_makary #semaglutide #zepbound
